Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development ; volume:12 ; number:1 ; day:20 ; month:9 ; year:2022 ; pages:1-14 ; date:12.2022
Scientific reports ; 12, Heft 1 (20.9.2022), 1-14, 12.2022
- Creator
-
Page, Natalie
Wappett, Mark
O’Dowd, Colin R.
O’Rourke, Martin
Gavory, Gerald
Zhang, Lixin
Rountree, J. S. Shane
Jordan, Linda
Barker, Oliver
Gibson, Hayley
Boyd, Caroline
Feutren-Burton, Stephanie
McLean, Estelle
Trevitt, Graham
Harrison, Timothy
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-20208-5
- URN
-
urn:nbn:de:101:1-2022120721153709216231
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Page, Natalie
- Wappett, Mark
- O’Dowd, Colin R.
- O’Rourke, Martin
- Gavory, Gerald
- Zhang, Lixin
- Rountree, J. S. Shane
- Jordan, Linda
- Barker, Oliver
- Gibson, Hayley
- Boyd, Caroline
- Feutren-Burton, Stephanie
- McLean, Estelle
- Trevitt, Graham
- Harrison, Timothy
- SpringerLink (Online service)
Other Objects (12)
Understanding subtype-selective allosteric modulation of GABAAreceptors
Development of compounds suitable for NMR quantum computing
Development of supraparticles suitable for magnetic identification tags
Development of Compounds Suitable for NMR Quantum Computing
Development of 18F-labeled subtype selective orexin and muscarinic receptor ligands for imaging by positron emission tomography
Systematic development of formulations suitable for pulmonary applications by nebulisation
Map Symbol Development for 3D Cartography suitable in VR-Environments
Development of a copper-clioquinol formulation suitable for intravenous use
Size selective recognition of small esters by a negative allosteric hemicarcerand
Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
Discovery and molecular basis of subtype-selective cyclophilin inhibitors
Structure‐Based Evolution of Subtype‐Selective Neurotensin Receptor Ligands
Understanding subtype-selective allosteric modulation of GABAAreceptors
Development of compounds suitable for NMR quantum computing
Development of supraparticles suitable for magnetic identification tags
Development of Compounds Suitable for NMR Quantum Computing
Development of 18F-labeled subtype selective orexin and muscarinic receptor ligands for imaging by positron emission tomography
Systematic development of formulations suitable for pulmonary applications by nebulisation
Map Symbol Development for 3D Cartography suitable in VR-Environments
Development of a copper-clioquinol formulation suitable for intravenous use
Size selective recognition of small esters by a negative allosteric hemicarcerand
Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
Discovery and molecular basis of subtype-selective cyclophilin inhibitors
Structure‐Based Evolution of Subtype‐Selective Neurotensin Receptor Ligands
Understanding subtype-selective allosteric modulation of GABAAreceptors
Development of compounds suitable for NMR quantum computing
Development of supraparticles suitable for magnetic identification tags
Development of Compounds Suitable for NMR Quantum Computing
Development of 18F-labeled subtype selective orexin and muscarinic receptor ligands for imaging by positron emission tomography
Systematic development of formulations suitable for pulmonary applications by nebulisation
Map Symbol Development for 3D Cartography suitable in VR-Environments
Development of a copper-clioquinol formulation suitable for intravenous use
Size selective recognition of small esters by a negative allosteric hemicarcerand
Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
Discovery and molecular basis of subtype-selective cyclophilin inhibitors